Global Information
회사소개 | 문의

심장 재동기화 치료 제세동기(CRT-D) : 의료기기 파이프라인 평가

Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2018

리서치사 GlobalData
발행일 2018년 06월 상품 코드 358888
페이지 정보 영문 89 Pages
가격
US $ 2,500 ₩ 2,805,500 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,611,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,416,500 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


심장 재동기화 치료 제세동기(CRT-D) : 의료기기 파이프라인 평가 Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2018
발행일: 2018년 06월 페이지 정보 : 영문 89 Pages

한글목차

현재 개발중인 심장 재동기화 치료 제세동기(CRT-D) 파이프라인 제품 정보에 대해 조사 분석했으며, 주요 제품과 프로젝트, 주요 기업, 임상시험 정보, 최근 동향 등의 정보를 전해드립니다.

제1장 목차

제2장 서론

  • 심장 재동기화 치료 제세동기(CRT-D) 개요

제3장 개발중인 제품

  • 심장 재동기화 치료 제세동기(CRT-D) - 파이프라인 제품 : 개발 단계별
  • 심장 재동기화 치료 제세동기(CRT-D) - 파이프라인 제품 : 부문별
  • 심장 재동기화 치료 제세동기(CRT-D) - 파이프라인 제품 : 지역별
  • 심장 재동기화 치료 제세동기(CRT-D) - 파이프라인 제품 : 규제 경로별
  • 심장 재동기화 치료 제세동기(CRT-D) - 파이프라인 제품 : 승인 시기별(예정)
  • 심장 재동기화 치료 제세동기(CRT-D) - 파이프라인 제품 : 진행중인 임상시험

제4장 심장 재동기화 치료 제세동기(CRT-D) : 개발중인 파이프라인 제품(기업별)

  • 심장 재동기화 치료 제세동기(CRT-D) 기업 - 파이프라인 제품 : 개발 단계별
  • 심장 재동기화 치료 제세동기(CRT-D) - 파이프라인 제품 : 개발 단계별

제5장 심장 재동기화 치료 제세동기(CRT-D) 기업과 제품 개요

  • Boston Scientific Corp
  • IRadimed
  • John Hopkins University
  • LivaNova PLC
  • Mayo Clinic US
  • Medtronic plc
  • NewPace Ltd
  • St. Jude Medical, Inc.
  • TransWorld Med Corp

제6장 심장 재동기화 치료 제세동기(CRT-D) : 최근 동향

제7장 부록

도표

LSH 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문목차

GlobalData's Medical Devices sector report, "Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2018" provides an overview of Cardiac Resynchronisation Therapy (CRT) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiac Resynchronisation Therapy (CRT) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Cardiac Resynchronisation Therapy (CRT) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cardiac Resynchronisation Therapy (CRT) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cardiac Resynchronisation Therapy (CRT) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Cardiac Resynchronisation Therapy (CRT) Overview 6

3 Products under Development 7

  • 3.1 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 7
  • 3.2 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Segment 8
  • 3.3 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Territory 9
  • 3.4 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Regulatory Path 10
  • 3.5 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Estimated Approval Date 11
  • 3.6 Cardiac Resynchronisation Therapy (CRT) - Ongoing Clinical Trials 12

4 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products under Development by Companies 13

  • 4.1 Cardiac Resynchronisation Therapy (CRT) Companies - Pipeline Products by Stage of Development 13
  • 4.2 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 14

5 Cardiac Resynchronisation Therapy (CRT) Companies and Product Overview 15

  • 5.1 AI Medical Semiconductor Ltd. Company Overview 15
    • 5.1.1 AI Medical Semiconductor Ltd. Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.2 Boston Scientific Corp Company Overview 16
    • 5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.3 DHS Medical Company Overview 20
    • 5.3.1 DHS Medical Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.4 EBR Systems Inc Company Overview 22
    • 5.4.1 EBR Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.5 IRadimed Corp Company Overview 26
    • 5.5.1 IRadimed Corp Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.6 Johns Hopkins University Company Overview 27
    • 5.6.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.7 LivaNova PLC Company Overview 28
    • 5.7.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.8 Mayo Clinic Company Overview 29
    • 5.8.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.9 Medtronic plc Company Overview 30
    • 5.9.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.10 MicroPort Scientific Corp Company Overview 36
    • 5.10.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.11 NewPace Ltd Company Overview 37
    • 5.11.1 NewPace Ltd Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.12 Odem Medical Ltd Company Overview 40
    • 5.12.1 Odem Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.13 St. Jude Medical LLC Company Overview 41
    • 5.13.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.14 TransWorld Med Corp Company Overview 42
    • 5.14.1 TransWorld Med Corp Pipeline Products & Ongoing Clinical Trials Overview 42

6 Cardiac Resynchronisation Therapy (CRT)- Recent Developments 43

  • 6.1 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 43
  • 6.2 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 43
  • 6.3 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 45
  • 6.4 Apr 03, 2018: Nihon Kohden Announces Change in Representative Director and Director 46
  • 6.5 Mar 10, 2018: LifeVest Wearable Defibrillator Reduces Total Mortality By 36 Percent At 90 Days 46
  • 6.6 Mar 07, 2018: EBR Systems Initiates Global Trial of World's Only Wireless CRT Pacing Technology 47
  • 6.7 Mar 01, 2018: Results of Landmark Wearable Defibrillator Trial to Be Presented as ACC.18 Late-Breaker 48
  • 6.8 Mar 01, 2018: First BIOTRONIK Pacemakers in Japan Approved for 3 Tesla Full-Body MRIs 49
  • 6.9 Feb 28, 2018: LivaNova Announces Fourth Quarter and Full-Year 2017 Results 50
  • 6.10 Feb 27, 2018: genedrive Receives Significant Funding for TB Test Development 52
  • 6.11 Feb 26, 2018: Medtronic Recalls Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillators Due to Manufacturing Error Preventing Electrical Shock Delivery 52
  • 6.12 Feb 26, 2018: Tissue Regenix Group: Launch of TRX BioSurgery and new distributor agreement 53
  • 6.13 Feb 07, 2018: Caisson Interventional Expanding in Maple Grove 53
  • 6.14 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 54
  • 6.15 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 56
  • 6.16 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 57
  • 6.17 Jan 08, 2018: LivaNova Announces Matthew J. Dodds as Senior Vice President, Corporate Development 57
  • 6.18 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region 57
  • 6.19 Dec 19, 2017: Bluetooth Pacemakers Offer Convenience and Cost Savings 58
  • 6.20 Dec 13, 2017: Electric eel inspires new power source 59
  • 6.21 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 60
  • 6.22 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 63
  • 6.23 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 64
  • 6.24 Nov 02, 2017: Mexican doctors safely reuse donated pacemakers after sterilization 65
  • 6.25 Nov 02, 2017: LivaNova Reports Third Quarter 2017 Results 66
  • 6.26 Nov 02, 2017: Nihon Kohden opens a sales branch in Kenya 67
  • 6.27 Oct 31, 2017: AHA/ACC/HRS Publish New Guidelines on the Wearable Cardioverter Defibrillator for Patients at Risk of Sudden Cardiac Death 68
  • 6.28 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017 69
  • 6.29 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 70
  • 6.30 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 71
  • 6.31 Sep 27, 2017: ZOLL Canada Wins Tender to Equip Province of Quebec Paramedic Services with ZOLL X Series Monitor/Defibrillators 72
  • 6.32 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 72
  • 6.33 Aug 21, 2017: BIOTRONIK US Launches Smallest MR Conditional Quadripolar Cardiac Resynchronization Therapy Pacemaker 75
  • 6.34 Aug 09, 2017: LivaNova Reports Second Quarter 2017 Results 76
  • 6.35 Aug 03, 2017: BIOTRONIK's Newest CRT-D Device with MultiPole Pacing Now Available in Japan 77
  • 6.36 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 78
  • 6.37 Jul 19, 2017: Fewer Leads, Fewer Complications: BIOTRONIK US Launches Proven DX Technology For Heart Failure Patients 79
  • 6.38 Jul 13, 2017: Nihon Kohden Selected for FTSE4Good Index Series and FTSE Blossom Japan Index 80
  • 6.39 Jul 10, 2017: BIOTRONIK's New Quadripolar CRT-P with More Pacing Options Now Available in Japan 80
  • 6.40 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 81
  • 6.41 Jun 20, 2017: EBR Systems Awarded Favorite Innovation for WiSE CRT at 2017 EHRA Europace Cardiostim Congress 83
  • 6.42 Jun 13, 2017: Nihon Kohden to reorganize its group companies in India 84
  • 6.43 Jun 12, 2017: LivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel 84

7 Appendix 86

  • 7.1 Methodology 86
  • 7.2 About GlobalData 89
  • 7.3 Contact Us 89
  • 7.4 Disclaimer 89

List of Tables

1.1 List of Tables

  • Table 1: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 7
  • Table 2: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Segment 8
  • Table 3: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Territory 9
  • Table 4: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Regulatory Path 10
  • Table 5: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Estimated Approval Date 11
  • Table 6: Cardiac Resynchronisation Therapy (CRT) - Ongoing Clinical Trials 12
  • Table 7: Cardiac Resynchronisation Therapy (CRT) Companies - Pipeline Products by Stage of Development 13
  • Table 8: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 14
  • Table 9: AI Medical Semiconductor Ltd. Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 10: Adaptive CRT And Vagal Stimulation Device - Product Status 15
  • Table 11: Adaptive CRT And Vagal Stimulation Device - Product Description 15
  • Table 12: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16
  • Table 13: Next Generation Quad Polar CRT-D - Product Status 16
  • Table 14: Next Generation Quad Polar CRT-D - Product Description 16
  • Table 15: NG3 Non Quad System - Product Status 17
  • Table 16: NG3 Non Quad System - Product Description 17
  • Table 17: Boston Scientific Corp - Ongoing Clinical Trials Overview 18
  • Table 18: Next Generation Quad Polar CRT-D - Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan 19
  • Table 19: DHS Medical Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 20: Drimmer - Product Status 20
  • Table 21: Drimmer - Product Description 20
  • Table 22: Twistek - Product Status 21
  • Table 23: Twistek - Product Description 21
  • Table 24: EBR Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 25: Second Generation WiSE CRT System - Product Status 22
  • Table 26: Second Generation WiSE CRT System - Product Description 22
  • Table 27: WiSE CRT System - Product Status 23
  • Table 28: WiSE CRT System - Product Description 23
  • Table 29: EBR Systems Inc - Ongoing Clinical Trials Overview 24
  • Table 30: WiSE CRT System - Multicenter, Prospective Evaluation of Safety and Performance of the WiCS-LV System in Patients Indicated for Cardiac Resynchronization Therapy 25
  • Table 31: WiSE CRT System - Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-responders and Previously Untreatable Patients: SOLVE CRT 25
  • Table 32: WiSE CRT System - WiCS-LV Post Market Surveillance Registry 25
  • Table 33: IRadimed Corp Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 34: MRI Defibrillator - Product Status 26
  • Table 35: MRI Defibrillator - Product Description 26
  • Table 36: Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 37: Cardiac Arrhythmia Termination Device - Product Status 27
  • Table 38: Cardiac Arrhythmia Termination Device - Product Description 27
  • Table 39: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 40: Triple-Site Ventricular (Tri-V) Pacing CRT-D - Product Status 28
  • Table 41: Triple-Site Ventricular (Tri-V) Pacing CRT-D - Product Description 28
  • Table 42: Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 43: Atrial Fibrillation Device - Product Status 29
  • Table 44: Atrial Fibrillation Device - Product Description 29
  • Table 45: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 46: Amplia MRI Quad CRT-D SureScan System - Multiple Point Pacing - Product Status 30
  • Table 47: Amplia MRI Quad CRT-D SureScan System - Multiple Point Pacing - Product Description 31
  • Table 48: Claria MRI Quad CRT-D SureScan System - Multiple Point Pacing - Product Status 31
  • Table 49: Claria MRI Quad CRT-D SureScan System - Multiple Point Pacing - Product Description 31
  • Table 50: MRI Safe CRT-D - Product Status 32
  • Table 51: MRI Safe CRT-D - Product Description 32
  • Table 52: Medtronic plc - Ongoing Clinical Trials Overview 33
  • Table 53: Claria MRI Quad CRT-D SureScan System - Multiple Point Pacing - Optimizing Pacemaker Therapy Using Multi-point Pacing: The OPT-MPP Study 34
  • Table 54: Claria MRI Quad CRT-D SureScan System - Multiple Point Pacing - Personalized CRT - Multiple Point Pacing Post Approval Study 34
  • Table 55: Amplia MRI Quad CRT-D SureScan System - Multiple Point Pacing - Optimizing Pacemaker Therapy Using Multi-point Pacing: The OPT-MPP Study 35
  • Table 56: Amplia MRI Quad CRT-D SureScan System - Multiple Point Pacing - Personalized CRT - Multiple Point Pacing Post Approval Study 35
  • Table 57: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 58: PARADYM RF SonR CRT-D - Product Status 36
  • Table 59: PARADYM RF SonR CRT-D - Product Description 36
  • Table 60: NewPace Ltd Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 61: The Implantable Subcutaneous String Defibrillator (ISSD) - Product Status 37
  • Table 62: The Implantable Subcutaneous String Defibrillator (ISSD) - Product Description 37
  • Table 63: NewPace Ltd - Ongoing Clinical Trials Overview 38
  • Table 64: The Implantable Subcutaneous String Defibrillator (ISSD) - Surface ECG Signal Recording for the Implantable Subcutaneous String Defibrillator (ISSD) Detection Algorithm Performance Assessment 39
  • Table 65: Odem Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 66: Odem Device - Product Status 40
  • Table 67: Odem Device - Product Description 40
  • Table 68: St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 69: Quadra Allure MP CRT-P - MRI Labeling - Product Status 41
  • Table 70: Quadra Allure MP CRT-P - MRI Labeling - Product Description 41
  • Table 71: TransWorld Med Corp Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 72: Soul Mate - Pacemaker - Product Status 42
  • Table 73: Soul Mate - Pacemaker - Product Description 42
  • Table 74: Glossary 88

List of Figures

1.2 List of Figures

  • Figure 1: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 7
  • Figure 2: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Segment 8
  • Figure 3: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Territory 9
  • Figure 4: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Regulatory Path 10
  • Figure 5: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Estimated Approval Date 11
  • Figure 6: Cardiac Resynchronisation Therapy (CRT) - Ongoing Clinical Trials 12
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research